News|Articles|December 3, 2025
Accelerate Cell Line Development with GPEx® Lightning: Speed, Stability, and Industry-Leading Titers
Author(s)Catalent
Catalent’s GPEx® Lightning platform delivers stable, high-yield cell lines with unmatched speed—achieving titers up to 15g/L for mAbs and 11g/L for bispecifics. With 25-day pool generation and up to 12 weeks saved on development timelines, this offering sheet outlines key performance metrics and benefits that make GPEx® Lightning a game-changer for biologics developers.
Related Content
Trending on Pharmaceutical Technology
1
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
2
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
3
Shilpa CDMO to Launch as Dedicated Complex Small-Molecule Contract Development and Manufacturing Brand at CPHI Milan
4
Technology Transfer: Success Drivers and Obstacles Explained
5